Form 4: Elutia CSO Michelle Williams Executes RSU Vesting

Chief Scientific Officer Michelle LeRoux Williams acquired 12,500 shares of Elutia Inc. via RSU vesting, with 4,269 shares withheld for taxes.

Summary

• Michelle LeRoux Williams, Chief Scientific Officer of Elutia Inc., acquired 12,500 shares of Class A Common Stock on June 10, 2026, through the vesting of restricted stock units (RSUs).
• A total of 4,269 shares were withheld by the company to satisfy tax withholding obligations at a price of $1.04 per share.
• Following these transactions, the reporting person holds 118,052 shares of Class A Common Stock directly.
• The reporting person retains 25,000 unvested restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation, which does not signal a change in company outlook or performance.

Positives

• The transaction reflects the ongoing vesting of equity compensation, aligning the interests of the Chief Scientific Officer with shareholders.

Negatives

• The company withheld 4,269 shares to cover tax liabilities, which is a standard administrative procedure but reduces the net share acquisition for the executive.

Risks

• The value of the equity compensation is subject to market volatility in Elutia Inc. (ELUT) stock price.

Future Outlook

The remaining 25,000 restricted stock units are scheduled to vest quarterly through December 10, 2026, per the established vesting schedule.

Industry Context

StockSavvy.ai notes that routine RSU vesting for executive officers is a standard corporate governance practice in the biotechnology sector, typically having no material impact on market sentiment or company strategy.

Comparison to Industry Standards

• The use of RSU vesting as a component of executive compensation is consistent with standard practices for publicly traded biotech firms.
• Tax withholding via share reduction is a standard industry practice to manage executive tax liabilities.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• Continued quarterly vesting of remaining 25,000 RSUs through December 10, 2026.

Key Dates

Keywords

Elutia, ELUT, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Biotech